AustriaAustria

Pharma Criticizes Bioethics

06.08.2004

Vienna - Oliver Huber, General Secretary of the Austrian industry association Pharmig, criticized the recent sharp increase in fees for the work of the ethics commissions for clinical trials. As a direct result of the new Medicines Law (AMG) in force since May 1, fees have almost tripled. Until recently a pharmaceutical company in Austria paid some Euro1,500. This has risen to Euro4,000 for the Lead Ethics Commission alone plus Euro700 for any further evaluation centre. “SME will not be able to afford clinical trials in Austria any longer. Should the present situation prevail pharmaceutical companies will prefer to go abroad, where clinical trials are much more economical,” forecasts Huber. In Germany companies pay around Euro1,500, in Great Britain Euro1,000, and in France Euro1,450.

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/pharma-criticizes-bioethics.html

CHALLENGES FOR COMMERCIAL TEXT MINERS

How Content Access and Manual Process Hinder Mining Efforts

In biomedical R&D, researchers use text mining tools to extract and interpret facts, assertions and relationships from vast amounts of published information. Mining accelerates the research process, increases discovery and helps companies identify potential safety issues in the drug development pipeline. However, despite the many benefits of text mining, researchers face a number of obstacles before they even get a chance to run queries against the body of biomedical literature. Here are the three primary challenges for researchers as they build a collection of articles (or “corpus”) for their text mining projects: more...

Video

All videos

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • TIGENIX (B)1.28 EUR25.49%
  • BIOTECH PHARMACON (N)14.35 NOK13.89%
  • BIOFRONTERA (D)2.25 EUR10.29%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)14.00 SEK-39.13%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • MEDIGENE (D)7.58 EUR-5.60%

TOP

  • KARO BIO (S)39.40 SEK2378.0%
  • TRANSGENE (F)5.02 EUR74.9%
  • TIGENIX (B)1.28 EUR62.0%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.99 EUR-40.7%
  • BIONOR PHARMA (N)1.25 NOK-39.0%

TOP

  • KARO BIO (S)39.40 SEK4704.9%
  • ADOCIA (F)86.21 EUR426.6%
  • GALAPAGOS (B)53.99 EUR331.9%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • EVOCUTIS (UK)0.19 GBP-81.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)14.00 SEK-79.4%

No liability assumed, Date: 31.08.2015

Current issue

All issues